Effects of subcutaneous administration of 3-methylcholanthrene and 7,12-dimethylbenz[a]anthracene on spontaneous reticulum cell neoplasms in SJL/J mice.
Inbred 4-week-old and 16-week-old SJL/J mice were treated sc with either 150 or 450 microgram 3-methylcholanthrene (MCA). No difference was noted in their subcutaneous tumor response related to age. Although the incidences of reticulum cell neoplasms (RCN's) were the same in the controls for the 2 age groups, more 16-week-old animals developed RCN's after carcinogen treatment than did 4-week-old SJL/J mice. More 16-week-old mice developed both subcutaneous tumors at the site of MCA injection and systemic RCN's than did mice treated at 4 weeks of age. This incidence was related to the coinciding of the chronologic age of the mice for RCN development with the latency for chemical carcinogen-induced subcutaneous tumor development. Mice treated with 7,12-dimethylbenz[a]anthracene at 16 weeks of age responded in the same way as did those treated with MCA.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000008:administration & dosage*; D000367:Age Factors; D000818:Animals; D001551:Benz(a)Anthracenes / Q000008:administration & dosage*; D005260:Female; D007279:Injections, Subcutaneous; D016403:Lymphoma, Large B-Cell, Diffuse / Q000209:etiology*; D008748:Methylcholanthrene / Q000008:administration & dosage*; D051379:Mice; D008815:Mice, Inbred Strains; D012513:Sarcoma, Experimental / Q000209:etiology*; D012983:Soft Tissue Neoplasms / Q000209:etiology*
D001551:Benz(a)Anthracenes; D008748:Methylcholanthrene; D015127:9,10-Dimethyl-1,2-benzanthracene